X-linked adrenoleukodystrophy in women: a cross-sectional cohort study
- PMID: 24480483
- DOI: 10.1093/brain/awt361
X-linked adrenoleukodystrophy in women: a cross-sectional cohort study
Abstract
X-linked adrenoleukodystrophy is the most common peroxisomal disorder. The disease is caused by mutations in the ABCD1 gene that encodes the peroxisomal transporter of very long-chain fatty acids. A defect in the ABCD1 protein results in elevated levels of very long-chain fatty acids in plasma and tissues. The clinical spectrum in males with X-linked adrenoleukodystrophy has been well described and ranges from isolated adrenocortical insufficiency and slowly progressive myelopathy to devastating cerebral demyelination. As in many X-linked diseases, it was assumed that female carriers remain asymptomatic and only a few studies addressed the phenotype of X-linked adrenoleukodystrophy carriers. These studies, however, provided no information on the prevalence of neurological symptoms in the entire population of X-linked adrenoleukodystrophy carriers, since data were acquired in small groups and may be biased towards women with symptoms. Our primary goal was to investigate the symptoms and their frequency in X-linked adrenoleukodystrophy carriers. The secondary goal was to determine if the X-inactivation pattern of the ABCD1 gene was associated with symptomatic status. We included 46 X-linked adrenoleukodystrophy carriers in a prospective cross-sectional cohort study. Our data show that X-linked adrenoleukodystrophy carriers develop signs and symptoms of myelopathy (29/46, 63%) and/or peripheral neuropathy (26/46, 57%). Especially striking was the occurrence of faecal incontinence (13/46, 28%). The frequency of symptomatic women increased sharply with age (from 18% in women <40 years to 88% in women >60 years of age). Virtually all (44/45, 98%) X-linked adrenoleukodystrophy carriers had increased very long-chain fatty acids in plasma and/or fibroblasts, and/or decreased very long-chain fatty acids beta-oxidation in fibroblasts. We did not find an association between the X-inactivation pattern and symptomatic status. We conclude that X-linked adrenoleukodystrophy carriers develop an adrenomyeloneuropathy-like phenotype and there is a strong association between symptomatic status and age. X-linked adrenoleukodystrophy should be considered in the differential diagnosis in women with chronic myelopathy and/or peripheral neuropathy (especially with early faecal incontinence). ABCD1 mutation analysis deserves a place in diagnostic protocols for chronic non-compressive myelopathy.
Keywords: X-inactivation; adrenoleukodystrophy; carriers; faecal incontinence; myelopathy.
Comment in
-
Age-dependent penetrance among females with X-linked adrenoleukodystrophy.Brain. 2015 Feb;138(Pt 2):e325. doi: 10.1093/brain/awu232. Epub 2014 Aug 22. Brain. 2015. PMID: 25149409 No abstract available.
-
Reply: Age-dependent penetrance among females with X-linked adrenoleukodystrophy.Brain. 2015 Feb;138(Pt 2):e326. doi: 10.1093/brain/awu233. Epub 2014 Aug 22. Brain. 2015. PMID: 25149411 No abstract available.
Similar articles
-
X-linked adrenoleukodystrophy: pathogenesis and treatment.Curr Neurol Neurosci Rep. 2014 Oct;14(10):486. doi: 10.1007/s11910-014-0486-0. Curr Neurol Neurosci Rep. 2014. PMID: 25115486 Review.
-
[Screening for carrier and prenatal diagnosis of X-linked adrenoleukodystrophy].Zhonghua Er Ke Za Zhi. 2005 May;43(5):345-9. Zhonghua Er Ke Za Zhi. 2005. PMID: 15924749 Chinese.
-
[X-linked adrenoleukodystrophy].Ann Endocrinol (Paris). 2007 Dec;68(6):403-11. doi: 10.1016/j.ando.2007.04.002. Epub 2007 May 29. Ann Endocrinol (Paris). 2007. PMID: 17532287 Review. French.
-
X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.Biochim Biophys Acta. 2012 Sep;1822(9):1465-74. doi: 10.1016/j.bbadis.2012.03.012. Epub 2012 Mar 28. Biochim Biophys Acta. 2012. PMID: 22483867 Review.
-
Pathophysiology of X-linked adrenoleukodystrophy.Biochimie. 2014 Mar;98(100):135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. Biochimie. 2014. PMID: 24316281 Free PMC article. Review.
Cited by
-
Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders.Front Cell Dev Biol. 2020 Jul 29;8:690. doi: 10.3389/fcell.2020.00690. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32903870 Free PMC article.
-
In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment.Mol Ther. 2022 Jan 5;30(1):119-129. doi: 10.1016/j.ymthe.2021.05.022. Epub 2021 May 29. Mol Ther. 2022. PMID: 34058389 Free PMC article.
-
The difficulty in diagnosing X linked adrenoleucodystrophy and the importance of identifying cerebral involvement.BMJ Case Rep. 2015 May 12;2015:bcr2015209732. doi: 10.1136/bcr-2015-209732. BMJ Case Rep. 2015. PMID: 25969497 Free PMC article.
-
Gait Difficulties and Postural Instability in Adrenoleukodystrophy.Front Neurol. 2021 Jun 17;12:684102. doi: 10.3389/fneur.2021.684102. eCollection 2021. Front Neurol. 2021. PMID: 34220690 Free PMC article.
-
A Large Family with p.Arg554His Mutation in ABCD1: Clinical Features and Genotype/Phenotype Correlation in Female Carriers.Genes (Basel). 2021 May 19;12(5):775. doi: 10.3390/genes12050775. Genes (Basel). 2021. PMID: 34069712 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials